S5192

SB 222200

≥98% (HPLC), solid

• Synonim(y): (S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide
• Wzór empiryczny (zapis Hilla): C₂₆H₂₄N₂O
• Numer CAS: 174635-69-9
• Masa cząsteczkowa: 380.48
• NACRES: NA.77
• PubChem Substance ID: 24278254
• UNSPSC Code: 12352200
• MDL number: MFCD00944072
• Assay: ≥98% (HPLC)
• Form: solid

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• color: light yellow
• solubility: DMSO: soluble ~28 mg/mL, H₂O: insoluble
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c3ccccc3)c4ccccc4
• InChI: 1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1
• InChI key: MQNYRKWJSMQECI-QFIPXVFZSA-N
• Gene Information: human ... TACR2(6865), TACR3(6870)

Opis

Application

The pharmacodynamics profile of SB 222200 enables its use as a tool to study physiological and pathophysiological roles of NK-3 receptor in CNS-modulated behaviors.

Biochem/physiol Actions

Non-peptide NK₃ tachykinin receptor antagonist.

SB 222200 is a 2-phenyl-4-quinolinecarboxamides and a selective, reversible and competitive antagonist of human NK-3 receptor that effectively crosses the blood-brain barrier. It inhibits the NK-3 receptor-induced miosis or pupil constriction in conscious rabbits.^1,2

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Glaxo­Smith­Kline

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)